Article Text

PDF
AB0897 Risk Factors for Treatment Failure in Osteoporotic Patients with Rheumatoid Arthritis
  1. J.-W. Lee,
  2. K.-E. Lee,
  3. D.-J. Park,
  4. S.-S. Lee
  1. Chonnam National University Medical School, Gwangju, Korea, Republic Of

Abstract

Objectives No available anti-osteoporotic medication has been shown to completely prevent declines in bone mineral density (BMD) and the resulting increased risk of fracture. The objective of this study was to investigate the risk factors associated with treatment failure in osteoporotic patients with rheumatoid arthritis (RA).

Methods A retrospective cohort study of 103 patients with RA and osteoporosis was conducted. Baseline demographics, clinical characteristics, BMD, laboratory results and treatment-related data were collected from the patients' chart review. Patients were divided into two groups for comparison: those whose osteoporosis treatment was effective and those whose treatment failed. Risk factors for treatment failure were identified by univariate and multivariate logistic regression using variables that differed significantly between the groups.

Results Osteoporosis treatment failed in 66 of 103 patients (64.1%). During 14.01 months of (SD: 1.89 months) follow-up, non-adherence to bisphosphonate use (OR =12.997; p =0.006) was the most powerful risk factor for treatment failure. Daily glucocorticoid dosage ≥7.5 mg/day before the first BMD measurement (OR =6.230; p =0.015), immobilization >3 months (OR =4.773; p =0.006), and DAS28 ≥3.2 (OR =4.428; p =0.009) were also significantly related to treatment failure.

Conclusions Our findings indicate that osteoporosis treatment fails frequently in RA patients and adherence to bisphosphonate use, daily glucocorticoid dosage, immobilization, and DAS28 score should be taken into consideration when treating osteoporotic patients with RA.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.